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Thrombosis is a deadly malfunctioning of the hemostatic system occurring in numerous conditions and states,
from surgery and pregnancy to cancer, sepsis and infarction. Despite availability of antithrombotic agents and vast
clinical experience justifying their use, thrombosis is still responsible for a lion’s share of mortality and morbidity in
the modern world. One of the key reasons behind this is notorious insensitivity of traditional coagulation assays to
hypercoagulation and their inability to evaluate thrombotic risks; specific molecular markers are more successful but
suffer from numerous disadvantages. A possible solution is proposed by use of global, or integral, assays that aim
to mimic and reflect the major physiological aspects of hemostasis process in vitro. Here we review the existing
evidence regarding the ability of both established and novel global assays (thrombin generation, thrombelastography,
thrombodynamics, flow perfusion chambers) to evaluate thrombotic risk in specific disorders. The biochemical nature
of this risk and its detectability by analysis of blood state in principle are also discussed. We conclude that existing
global assays have a potential to be an important tool of hypercoagulation diagnostics. However, their lack of
standardization currently impedes their application: different assays and different modifications of each assay vary in
their sensitivity and specificity for each specific pathology. In addition, it remains to be seen how their sensitivity to
hypercoagulation (even when they can reliably detect groups with different risk of thrombosis) can be used for clinical
decisions: the risk difference between such groups is statistically significant, but not large.
Keywords: Global assays of hemostasis, Hypercoagulation, ThrombosisIntroduction
Thrombotic complications occur in many cases: they ac-
company or even induce innumerable disorders and states:
atherosclerosis, infarction, stroke, pregnancy, trauma, sur-
gery, sepsis, etc. Their danger is presently well recognized,
and there are regulations on the use of antithrombotic
agents for all patients with thrombotic risks. Such agents
are presently available in a huge variety [1] and include dir-
ect and indirect coagulation factors inhibitors, antagonists
of platelet activation and adhesion receptors, and also of
platelet signaling.
However, there are unmet needs with regard to identi-
fication the patients at risk of thrombosis, individual* Correspondence: ataullakhanov.fazly@gmail.com
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article, unless otherwise stated.selection and correct dosing of these drugs, in particular
for individual patients. There is always risk of bleeding
(1-3% for all antithrombotics at their recommended
doses), and brain hemorrhage can be no less fatal than
thrombosis. Traditional coagulation assays are insensi-
tive to hypercoagulation and unable to evaluate throm-
botic risks.
A possible solution is proposed by use of global, or
integral, assays [2-4] that aim to mimic and reflect the
major physiological aspects of hemostasis process
in vitro. Here we review the existing evidence regarding
the ability of both established and novel global assays
(thrombin generation, thrombelastography, thrombody-
namics, flow perfusion chambers) to evaluate throm-
botic risk in specific disorders. The biochemical nature
of this risk and its detectability by analysis of blood
state in principle are also discussed.Med Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Before speaking about thrombosis risk evaluation and
prediction of thrombosis using in vitro diagnostics, it is
essential to discuss the biochemical nature of thrombus
formation.
Venous thrombosis
Recent reviews on the venous thrombosis pathogenesis
can be found in [5,6]. The basic principles of it were for-
mulated by Virchov in 1859, who defined origin of
thrombosis in his famous triad of disorders in blood
composition, flow velocity or vascular wall. It is well
established that venous thrombi are formed mostly as a
result of fibrin formation (so-called ‘red’ thrombi rich in
fibrin and entrapped red blood cells) with little if any
contribution from platelet adhesion. It is not completely
clear, however, how this process is triggered. Venous
thrombi are attached to the vessel wall by fibrin [7], and
in most cases the wall remains undamaged [8]. The most
likely mechanism of triggering thrombosis involves
endothelial activation. Upon blood flow stagnation, in-
flammation and/or hypoxia endothelial cells release the
Weibel-Palade bodies containing von Willebrand factor
(vWF) of increased length and P-selectin. The release
enable attachment of platelets, monocytes, neutrophils
[9] and their microparticles. Activated by hypoxia, cyto-
kines, and lipopolysaccharides monocytes express Tissue
factor (TF) [10], which stimulates clotting activation.
Additional tissue factor is provided by microparticles de-
rived from monocytes, cancer cells [11] and probable
neutrophiles [9] depending on the primary disorder. Es-
sential role can be played by contact activation from
neutrophil extracellular traps (NET), extracellular chro-
matin fibers with a backbone of histones [9]; contribu-
tion of platelet- and endothelium-derived microparticles
is possible [12]. Depending on the balance between
procoagulant factors, their inhibitors and fibrinolysis,
this endothelium activation might develop into full-scale
thrombosis.
Arterial thrombosis
Arterial thrombosis is usually triggered by rupture of an
atherosclerotic plaque. This leads to externalization of
collagen, TF and vWF. As a result of rapid flow velocity
in arteries, the primary driving mechanism of arterial
thrombosis is platelet deposition with fibrin formation
playing a secondary, thrombus-stabilizing role [13,14].
This is confirmed by predominance of platelets in such
thrombin (so-called ‘white’ thrombi) and by efficiency of
antiplatelet agents [15]. Altered platelet adhesion and
aggregation due to increased vWF concentration, de-
creased ADAMTS13 (a metalloproteinase, that cleaves
vWF to smaller, less procoagulant forms), increased
in vitro platelet aggregation after low concentrations ofadenosine diphosphate and/or epinephrine (sticky platelet
syndrome) are associated with arterial thrombosis [16,17].
However, there are indications of hypercoagulation
state in the plasma of patients suffering from arterial
thrombosis: circulating factors XIa and TF were detected
in patients following ischemic cerebrovascular events
[18], in stable angina patients [19], in patients with sys-
tolic heart failure due to ischemic cardiomyopathy [20].
In some of the intravital arterial thrombosis animal
models monocyte- and endothelium-derived microparti-
cles were deposited in thrombi [11]. Even double-drug
antiplatelet therapy in acute coronary syndrome does
not prevent a ~10% yearly risk of a recurrence, while
addition of rivaroxaban significantly decreases the risk
[21]. These data indicate that blood coagulation contri-
bution in arterial thrombosis should not be neglected.Microvascular thrombosis
Originally, pathogenesis of thrombosis was primarily
studied in large blood vessels. However, there has been a
recent shift in the attention to the microvasculature and
to the microcirculatory occlusion [22]. Probably, an im-
portant factor in this shift is that the most informative
experimental models of thrombosis are microvascular
ones [23]. Development of microthrombosis is usually
related to TF expression by various cells, degradation of
TFPI by neutrophil elastase, fXII activation by NETs re-
leased by neutrophils and enhanced by their interaction
with platelets [24]. It is observed in multiple diseases
(sepsis [25], cancer [26], infarction [27], thrombotic
thrombocytopenic purpura [28]) and is a critical factor
in the development of disseminated intravascular coagu-
lation and organ dysfunction [29]. Among all types of
thrombosis, microvascular thrombosis is most of all as-
sociated with plasma ability to coagulate overall increase,
hypercoagulability [30].Specific causes of hypercoagulation
Hypercoagulation state, usually meaning increased ten-
dency of blood to clot, can be induced by numerous mo-
lecular mechanisms enumerated below.
Hypercoagulation in cancer is usually associated with
expression of TF, cancer procoagulant (CP) and adhesion
molecules. TF expression is induced by activation of on-
cogenes or inactivation of tumor suppressor genes [31].
Some of the circulating TF is associated with microparti-
cles [32,33] that also accelerate clotting by providing
additional phosphatidylserine. CP is a cysteine protease
with factor X activating properties [34]. Its role as a fac-
tor predictive of clinical thrombosis has not been suc-
cessfully demonstrated. Mice models demonstrated that
NETs also contribute significantly to hypercoagulation in
cancer [35]. Adhesion molecules allow direct interaction
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can induce formation of platelet microthrombi [36].
Normal pregnancy is associated with increase in fi-
brinogen (Fg), Factors VII, VIII, X, and VWF. Free pro-
tein S is decreased secondary to increased levels of its
binding protein, the complement component C4b. Plas-
minogen activator inhibitor type 1 (PAI-1) levels in-
crease 5-fold [37]. Levels of PAI-2, produced by the
placenta, increase dramatically during the third trimester
[38]. For some complication of pregnancy, increased
concentration of endothelial-derived and TF-positive mi-
croparticles was reported [39,40].
Hormonal contraceptives increases concentrations of
Fg, prothrombin (factor II) and factors VII, VIII and X,
and reduction in coagulation inhibitors, such as anti-
thrombin (AT) and protein S and tissue factor pathway
inhibitor (TFPI). On the other hand, fibrinolysis is also
stimulated: tissue plasminogen activator (tPA) activity is
increased, while that of PAI-1 is decreased [41].
Diabetes leads to increase in adhesion and aggregation
of platelets, as well as platelet-dependent thrombin for-
mation. Changes in the platelet reactivity occur at the
stage of megakariopoiesis. Leukocytes are also activated
and expose aminophospholipids and TF, express adhe-
sive molecules that promote interaction of leukocytes
with endothelium and formation of leukocyte-platelet
aggregates. Dysfunction of endothelium is observed.
Concentrations of VWF, factor VII, and Fg are in-
creased, those of AT, PC, endothelial thrombomodulin
(TM) are decreased. Platelets, monocytes, endothe-
lium demonstrate increased microparticle production.
Levels of PAI-1 and tPA are decreased [42].
To summarize, there are several immediate reasons of
high risk systemic thrombosis. First, there are materials
that directly activate coagulation: circulating contact
pathway-activating microparticles [43], circulating TF on
cells or microparticles (in cancer or diabetes), factor XIa
(ischemic cerebrovascular events, stable angina), сancerTable 1 The reasons of hypercoagulation in different states a
Background
state






Cancer ТF, NET, MP
Pregnancy TF, МР Fg, VII, VIII, X Free prote
Oral
contraceptives
Fg, II, VII, VIII, X ATIII, PS, T
Diabetes mellitus TF, platelet, monocyte,
endothelial МP
Fg, II, V, VII, VIII, and
X
ATIII, PC,
endotheliprocoagulant, bacteria. The second category includes
mechanisms that do not initiate clotting by themselves
but may promote clotting propagation by shifting coagu-
lation balance: increased level, activity or longevity of
pro-coagulant factors (congenital, pregnancy, oral con-
traceptives, mutations like prothrombin G20210A [44]
or factor V Leiden [45,46]), decreased concentration or
function of the anti-coagulant molecules (congenital or
consumptive deficiency of AT, PS, PC [47,48]), decreased
fibrinolysis, ADAMTS13, increased vWF [16]. The data
for several protrombotic states discussed in this article
are summarized in Table 1, which attempts to relate
mechanism of pro-coagulant changes, disorders that
cause them, and the types of thrombosis supported by
them.Detection of hypercoagulability: possible strategies
Nature of pre-disposition of an individual to thrombosis
may be either local or global. Local factors such as vessel
wall damage, atherosclerotic plaque formation or blood
flow stagnation remain naturally beyond functional la-
boratory assays of coagulation (although possibility to
detect some markers of inflammation and damage in
blood indirectly cannot be excluded). Other thrombotic
events can be directly associated with global changes in
blood composition. These systemic pro-thrombotic
changes are called hypercoagulation. When thrombosis
can be directly linked to hypercoagulability, several ways
to determine it exist.
One way is to detect the specific cause: change in the
coagulation factor or coagulation inhibitor concentra-
tion, presence of a circulating active factor, microparti-
cles, change in fibrinolysis factor, vWF concentrations.
While such research is important, these parameters ap-
pear to be innumerable and some of them (e.g. picomo-
lar concentrations of factors) are extremely hard to
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the blood to form thrombi.
Another strategy is to use molecular markers of on-
going thrombosis: D-dimers, fibrinopeptides, soluble fi-
brin monomers, thrombin-antithrombin complexes or
prothrombin fragments. This strategy is used widely and
has tremendous clinical advantages, but its major
drawback is that it detects traces of coagulation that
already occurred or goes presently at full rate. In dis-
seminated intravascular coagulation (DIC), you may
have great D-dimer in conjunction with zero clotting
due to coagulopathy.
Finally, the natural way to determine hypercoagulation
is to carry out coagulation experiments under condi-
tions, where contribution of the hypercoagulation factors
is significant (i.e. under conditions close in vivo). It turns
out that it is not significant for the traditional clotting
assays: when you stimulate clotting with huge concen-
trations of activators in APTT and PT, contribution of
the small quantities of circulating active factors is not
essential.
The possible solution to this might be global, or in-
tegral, assays of hemostasis [2-4]). They aim to mimic
(patho)physiogical processes with greater accuracy and
to involve all relevant processes, so they tend to deter-
mined overall hemostatic potential. Importantly, these
assays usually involve low activator concentration
(thrombin generation, TEG) or localization of the acti-
vator on the chamber wall (thrombodynamics, flow
perfusion chambers). This could indeed make them
sensitive to low concentrations of circulating agonists.
The purpose of the present review is to inventory the
available data in order to test the existing claim of the
global assays on their ability to predict thrombosis.
APTT and INR: are they indeed inappropriate as global
assays?
Till the present times, initial evaluation of hemostatic
status is done using APTT and INR assays. They are
sensitive, first of all, to deficiencies of coagulation factors
that usually result in their prolongation. Shortening of
clot times is rare and is often attributed to pre-analytical
errors (that play a great role in diagnostics, as it is very
easy to induce hypercoagulation by insufficiently careful
handling of whole blood). When dealing with throm-
bosis INR application is usually limited to assess the
effectiveness of vitamin K doses [49].
However, there are reports that some thrombotic dis-
orders may be detected by changes in APTT. Mina et al.
demonstrated that APTT shortening reliably indicates
abnormal factors V, XI, XII, VWF antigen and collagen-
binding activity, and the level of procoagulant phospho-
lipids, as assessed using a novel assay procedure (XACT)
[50]. It is not clear whether factor VIII increase canshorten APTT. APTT shortening has also been associ-
ated with high levels of biochemical markers of
thrombin generation and fibrin deposition such as
prothrombin fragment 12, thrombin-antithrombin
complex, and D-dimer [51]. Tripodi et al showed that
shortened APTT is a risk factor for deep vein throm-
bosis. In patients who had an APTT ratio (coagulation
time of test-to-reference plasma) smaller than the fifth
percentile of the distribution in controls, the odds ra-
tio (OR) for VTE was 2.4 and was independent of
inherited thrombophilic abnormalities. Median APTT
ratio values were 0.97 (range: 0.75-1.41) for patients
and 1.00 (range: 0.72-1.33) for controls (P < .001) [52].
Prospective observation of a large group (918 patients)
with spontaneous venous thrombosis revealed that
APTT ratio was significantly longer in patients with-
out thrombosis recurrence (0.97 ± 0.09 vs. 0.93 ± 0.09,
P < 0.001) The relative risk (RR) of recurrence among
patients with a APTT ratio or < 0.95 was 1.7 [53].
Legnani et al. discovered that venous thrombosis re-
currence risk after cancelling anticoagulation was more
than twofold higher in patients with ratio < or =0.90 versus
those of the reference category (Relative risk (RR): 2.38)
[54]. The data indicating predictive value of APTT are
given in Table 2.
An important version of APTT is so-called clot wave-
form analysis that considers the entire optical density
change curve, not only clot time. This assay is even
included among the global assays [2-4]. In particular,
two-phase curve in this assay is a sensitive and specific
predictor of DIC (85% and 92%, respectively) [56]. This
curve is explained by precipitation of C-reactive protein
with VLDL upon addition of Са [57].
So, it seems that APTT is working in some cases of
pro-coagulant changes in plasma, but these successes
are mostly associated with changes in the concentrations
of coagulation factor components, not with appearance
of coagulation-activating circulating material. It is most
likely that potent artificial clotting activation in APTT
(and even stronger activation in INR) does not allow ob-
servation of small effects produced by circulating TF,
fXIa, or microparticles. Protein C pathway does not
function in APTT unless activated protein C is added,
but even then thrombin generation using the same
approach is more sensitive [58]. APTT does not include
fibrinolysis in any way. Probably that is why APTT has
no predictive value as a thrombosis risk marker fol-
lowing surgery [59,60], trauma [61], diabetes [55,62],
cancer [63]. Data about pregnancy are contradictive
[64,65]. The main hypercoagulation factor detected by
APTT shortening is most likely increased concentra-
tion or activity of coagulation factor predecessors. For
example, in the study [54], increase of the recurrence
risk of VT disappeared after adjustment for factor
Table 2 Examples of АPPT ratio response to different procoagulant states
Procoagulant state Number of patients
in study group
Data range in control
group, mean ± SD
unless otherwise
indicated
Data range in group
with hypercoagulation,
mean ± SD unless
otherwise indicated
Significance Predictive value Reference Comments




<0.001 APTT ratio < 0.87 OR = 2.4 [52] Retrospective study.
Recurrence after first
unprovoked VTE
918 with a first VTE
101 – with recurrence
0.97 ± 0.09 0.93 ± 0.09 0.001 APTT ratio < 0.95 RR = 1.79 [53] Prospective study.
Analysis was performed





628 with a first VTE,
71 – with recurrence
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themselves had better predictive capacity of recur-
rence risk (RR = 2.38 for APTT ratio < 0.90, RR = 3.01;
3.06; 2.14 for increased levels of fVIII, dIX and fXI,
respectively). Still, thrombophilic risk factors G1691A-
factor V and G20210A-factor II did not differ significantly
in groups with normal and shortened APTT [51].
Hypercoagulation and thrombin generation
Thrombin generation is one of the two best developed
and tested global assays of hemostasis. Invented in its
present form by the team of Coenraad Hemker of
Maastricht University [66], the method uses a thrombin-
sensitive chromogenic or, recently, fluorogenic substrate.
From the velocity of its cleavage, thrombin concentra-
tion as a function of time is obtained and used for
diagnostic purposes; it usually has a characteristic
bell-shape. Such parameters as endogenous thrombin
potential (ETP, area under the thrombin generation
curve) are among the most widely used, and their cor-
relation with clinical phenotype is well established.
Interestingly, most of the thrombin generation curve
is observed after clot formation, and its meaning is
still a subject of debate [67].
There are presently numerous modifications of
thrombin generation including several commercially
available versions. Typically, the assay is performed in
platelet free plasma supplemented with phospholipids;
use of platelet-rich plasma is also possible. Triggering
is done by picomolar TF concentration, although other
stimuli can be used. Thrombin generation experiments
can be done with TM, protein C-activating enzymes or
simply activated protein C to better highlight the pro-
tein C pathway.
Tripodi et al. reported that patients with increased
thrombin generation in the presence of TM have higher
risk of recurrent venous thromboembolism. Those with
ETP > 960 nM · min or thrombin peak >193 nM had
hazard ratios (HR) for recurrent VTE of 3.41 or 4.57 as
compared with those with an ETP <563 nM · min or
peak <115 nm. Patients with lag-time <14.5 min had HR
of 3.19 as compared with those with lag-time >20.8 min
[68]. The same was reported by Besser et al.: after ad-
justment for D-dimer, thrombophilia, sex, and whether
or not the first event was unprovoked, a high ETP
remained a significant predictor of recurrence, HR 2.6
[69]. In a similar study of Hron et al., patients without
recurrent VTE had lower thrombin generation than pa-
tients with recurrence (mean [SD], 349.2 [108.0] nM vs
419.5 [110.5] nM, respectively; P < .001). Compared with
patients who had thrombin generation lower than 400
nM, the relative risk (RR) of recurrence was 2.4 [70].
Interestingly, van Hylckama Vlieg et al. did not find any
predictive value for thrombosis risk though this mightbe due to a different experimental design [71]. Chaireti
et al. found, paradoxically, that ETP immediately
after thrombosis is lower in the group of thrombosis
recurrence. If blood was collected 1-2 months after
cancellation of anticoagulants, their ETP was insignifi-
cantly higher [72].
Increased ETP in platelet-rich plasma was reported for
patients after ischemic stroke [73]. In PPP, increased
thrombin peak predicted stroke for women and did not
correlated with stroke in men (hazard ratio 1.04 for
men, 1.7 for women) [74]. ETP is increased in almost
any thrombophilia including G20210A mutation [75],
AT deficiency [76], factor V Leiden [77] and protein S
deficiency [78] (if experiments are with thrombomodu-
lin), upon oral contraceptive use [79], in cancer [80].
ETP is increased in pregnancy [81,82], but seems to
reach a plateau in the first trimester [83], while D-dimer,
F1 + 2 and TAT increased, and there was no correlation
between parameters of ETP assay and markers of in vivo
thrombin generation. Lack of this correlation was con-
firmed in [80]. Patients with diabetes had significantly
higher thrombin peak [55,62], probably because of in-
creased level of factors II, V, VII, VIII, and X and de-
creased protein C [62].
Thrombin peak was reported to correlate with micro-
particle count, in particular when thrombin generation
is performed without adding external activators and
phospholipids [55]. Ollivier et al. found that lag time in
recalcified plasma is sensitive to TF and does not
affect the peak, while peak is sensitive to phospho-
lipids. Distinct contributions of these two factors in
cancer patients’ plasmas were differentiated in [84].
Lipopolysaccharides reliably decreased lag time [85].
It appears that thrombin generation is sensitive to
various hypercoagulation factors depending on the
design: to levels of factors II, V, Fg, AT at high TF
(13.6рМ); to fXII, Fg, AT, free TFPI at low TF (1pM)
[86], as well as to fVIII and fIX [87]; to protein C
pathway defects upon addition of thrombomodulin or
protein C activator [88]; to circulating TF when per-
formed without activators; to lipids when performed
without externally added lipids. Decrease of activation
level increases overall sensitivity but increases deviation.
Difference in the mean parameter values for patients with
and without thrombosis is usually significant, but SDs usu-
ally overlap and it is complicated to transform such result
into a clinical recommendation (Table 3). Although throm-
bin generation test standardization is presently under devel-
opment [2] its lack restricts the method application.
Fibrinolysis and use of whole blood are currently be-
yond the available versions of this method, although
some preliminary on thrombin generation in whole
blood appeared [89]. There are no clinical data for
thrombotic states for this version yet.









Data range in control
group, mean ± SD
unless otherwise
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Data range in group
with hypercoagulation,
mean ± SD unless
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ETP, nM∙min 1361 ± 499 0.122 1 tertile compared







IIa max, nM 232 ± 82 IIa max, nM 187 ± 89 0.005 HR = 3.09
Tlag, min 12 ± 6 Tlag, min 13 ± 5 0.319 HR = 2.29
1 pM TF 1 uM
PL 4 nM TM
ETP, nM∙min 986 ± 422 ETP, nM∙min 763 ± 468 0.009 HR = 3.35 [68]
IIa max, nM 201 ± 75 IIa max, nM 148 ± 88 <0.001 HR = 4.49













[69] Prospective study. Analysis
was performed 2-3 months
after completion of
anticoagulant therapy.
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DVT HR = 1.7
[71] Analysis was performed
3 months after completion
of anticoagulant therapy.
173 with a first
provoked VT
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105 with a first
VTE, 40 – with
recurrence
5 pM TF 4 uM
PL
ETP, nM∙min 1671 ± 514 ETP, nM∙min 1491 ± 536 0.111 [72] Prospective study. Analysis
was performed upon
diagnosis of VTEIIa max, nM 302 ± 91 IIa max, nM 261 ± 125 0.058
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geometric mean and
interquartile range ETP,
nM∙min 1720 (1572 - 1978)
HR = 0.88/sd [74] Prospective study.
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(304.9 - 357.8)

























Table 3 Examples of Trombin generation response to different procoagulant states (Continued)
Stroke
(women)
IIa max, nM 333.6
(311.0 - 372.4)













HR = 1.09/sd [74] Prospective study
IIa max, nM 333.0
(308.0 - 365.0)
IIa max, nM 330.3
(301.9- 357.8)














range ETP, nM∙min 1358
(1190–1492)




IIa max, nM 292 (267–330) IIa max, nM 349 (307–385) <0.001
Tlag, min 2.54 (2.46–2.84) Tlag, min 2.74 (2.46–3.04) 0.268
3 homozigote ETP, nM∙min 1661
(1451–1976)
[75]
IIa max, nM 466 (446–470)
Tlag, min 3.06 (2.14–5.08)
AT III-inherited
deficiency
9 - controls 18
Type I-IIRS/PE
5 pM TF 4 uM
PL




IIa max, nM 377.3 ± 49.1 IIa max, nM 493.4 ± 75.0
17 -IIHBS
heterozygote
ETP, nM∙min 2142 ± 464
IIa max, nM 427.2 ± 98.3
8 - Cambridge
II heterozygote
ETP, nM∙min 2211 ± 268






71.6 pM TF 3.2
uM PL
median (25th to 75th
percentile) ETP, nM∙min
4386 (3804-4890)
median (25th to 75th
percentile) ETP, nM∙min
4475 (4087-4915)

















IIa max, nM 264 (97–432) IIa max, nM 303 (207–434) <0.001
Tlag, min 7.8 (4.7–18.4) Tlag, min 5.9 (4.5–11.5) <0.001
1 pM TF 1 uM






IIa max, nM 256 (79–433) IIa max, nM 297 (216–427) 0.001
Tlag, min 10.4 (6.3–25.8) Tlag, min 7.8 (5.6–13.6) <0.001
43 patients, 60
controls





IIa max, nM 151 (41–289) IIa max, nM 202 (128–350) <0.001

















5 pM TF 4 uM
PL
ETP, nM∙min 1566.4 ± 240.7 ETP, nM∙min 1876.5 ±
390.0
<0.001 [62]
IIa max, nM 252.8 ± 44.6 IIa max, nM 308.9 ± 39.5 <0.001







5 pM TF 20 uM
PL 0.1 mg/ml
CTI
ETP, nM∙min 1553 ± 567 pre-pregnancy ETP,




nancy P < 0.001
[82]
IIa max, nM 81 ± 41
Early ETP, nM∙min 2157 ±
466
IIa max, nM 159 ± 100 IIa max, nM 219 ± 117
Late ETP, nM∙min 2410 ±
543





5 pM TF 4 uM
PL
TG on normal pooled
plasma was significantly
lower than TG on pregnant
women. The exact parameter’s
values weren’t shown




IIa max, nM 366 ± 43
2nd Trimester
(n = 42)
ETP, nM∙min 2067 ± 326
IIa max, nM 374 ± 42
3rd Trimester
(n = 23)
ETP, nM∙min 1915 ± 261
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The most direct way to characterize clot formation is by
rheometry, which has additional advantage of being in-
dependent of optical phenomena and easily applied in
whole blood. There are numerous rheological ap-
proaches, and the best studied of them is thrombelasto-
graphy. It is the most ancient global assay of hemostasis,
where clot formation and platelet aggregation are evalu-
ated simultaneously using forced oscillations rheometry.
Thrombelastography (TEG or ROTEM) has found a
wide application for patients undergoing surgery as an
alternative to APTT and INR that are not sensitive to
hypercoagulation in this state [59,90]. A paper by Yue
Dai et al. carefully examines reports between 1980 and
2008 about possibility to predict thrombosis using TEG,
and majority of them answered positively. However, sen-
sitivity and specificity varied between 0%-100% and 62%-
92% respectively, with odds ratio reported between 1.5
and 27.7 [91] thus preventing meta-analysis. Later re-
ports confirmed predictive value of maximal amplitude
(MA) and clot firmness G (G = 5000 MA/100 – MA) as
independent indicators of recurrent ischemic stroke after
surgery (OR = 1.192, p = 0.022) [92]; the same was ob-
tained for other thrombotic complications Similar data
were obtained for ROTEM [90]. MA is believed to be
mostly dependent on platelet function and fibrinogen
concentration [93]; this might explain why it does not
correlate with APTT and INR [92].
TEG revealed hypercoagulation in patients with pros-
tate cancer, in particular in the group with metastases,
in agreement with the increase of TF-expressing micro-
particles. Thrombotic complications arose in 7 out of 22
patients with increased TEG, while APTT and INR were
normal [63]. TEG was able to detect hypercoagulation in
patients with breast and colorectal cancer [94], gastro-
intestinal system tumors, respiratory system tumors, and
miscellaneous tumors [95], after DVT [96], but not after
cerebral venous thrombosis [97]. TEG is increased only
in 57% patients with thrombophilia [98], this lack of sen-
sitivity is confirmed in [97,99]. TEG reliably detect
hypercoagulation in pregnancy that increases over the
whole course [100-102] by parameters r, K, alfa, MA.
Like thrombin generation, thrombelastography is
established to detect hypercoagulation, and there is
evidence of both its shift in patient groups with
known thrombotic risks and in patient groups with
clinically occurring thrombosis. The pattern of sensi-
tivity differs from that of thrombin generation: e.g.,
TEG is better in pregnancy but worse in thrombophi-
lia. Still, wider use of this method suffers from the
same shortcomings: deviations between donors are
even greater that in thrombin generation resulting in
poor difference between risks (Table 4), and there is
lack of standardization.Novel assays
There are several innovative global assays that are not
used widely yet but may be promising as they include
some really important aspects. Some of them are ver-
sions of the existing ones (e.g. there are numerous rheo-
metric approaches beyond TEG [105]), while others use
completely innovative principles. Below we discuss the
methods that have been tested with regard to the pro-
thrombotic sensitivity.
Thrombin-and-plasmin generation
There are several versions of the method to detect
thrombin and plasmin at once [106-108]. Increased co-
agulation and impaired fibrinolysis are detected by
means of overall hemostasis potential in patients with
acquired arterial thrombotic events and vasculopathies,
such as diabetic patients with microvascular complica-
tions, 15 patients with preeclampsia, 16 and elderly
female patients with coronary heart disease [106]. Al-
though the data are very scarce, this method is interest-
ing as the only known alternative to TEG with regard to
fibrinolysis evaluation.
Thrombodynamics
A novel strategy of blood coagulation testing is proposed
in the thrombodynamics assay that has been developed
and used as a research tool for almost two decades and
became commercially available for clinical labs in 2012.
The central idea of the method is monitoring spatial
fibrin formation initiated by immobilized tissue factor in
plasma by videomicroscopy [109], so that clot is initially
formed on the activator and then propagates into
plasma. A version of the assay exists that can determine
thrombin formation as a function of time and space in
parallel with fibrin [110].
The idea behind this is to take into account spatial
heterogeneity of blood coagulation, in other words, the
fact that clotting initiation and propagation occurs in
spatially separated regions [111]. In agreement with the
wound clotting in vivo, tissue factor is located on the
surface, and clot propagates because of coagulation fac-
tor activation and diffusion [112]. Importantly, separ-
ation of the activation and propagation phases makes
the assay particularly sensitive to the presence of coagu-
lation activators in plasma such as circulating tissue fac-
tor [112] or factor XIa [43]. Spatial clot formation
velocity indicates overall procoagulant potential, while
formation of activator-independent spontaneous clot-
ting centers may indicate presence of microparticles
and long-lived coagulation factors [43]. Pre-analytical
standardization for this assay has also recently become
available [113].
These biochemical findings have been confirmed by
several preliminary studies. Hypercoagulation detected
Table 4 Examples of TEG response to different procoagulant states
Procoagulant
state
Number of patients in
study group
TEG version Data range in
control group,
mean ± SD unless
otherwise
indicated
Data range in group
with hypercoagulation,
mean ± SD unless
otherwise indicated






Rankin Scale within a year
91-Favorable outcome
Citrate plasma was mixed
with kaolin, and loaded in
a heparinise-coated cup
means ± SE MA,
mm 63.2 ± 0.5
means ± SE MA,
mm
66.1 ± 0.6
<0.001 Prediction of unfavorable
outcome At higher tertile





240 patients undergoing a
wide variety of surgical




within 4 min of collection









152 critically ill patients in












65/65 Recalcified citrate plasma R, min 7.8 ± 2.5 R, min 6.1 ± 1.8 <0.001 [102]
K, min 2.7 ± 2.3 K, min 1.4 ± 0.5
Alfa, deg 57.7 ± 11.6 Alfa, deg 70.6 ± 6.5
MA, mm 61 ± 5.9 MA, mm 71 ± 3.8
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firmed by subsequent increase of D-dimers and occa-
sional thrombosis [114]. Spontaneous clotting and
increase spatial clot growth velocity were observed in
patients with well-known thrombotic risks suffering
from lymphomas, lymphogranulomatosis, thrombophi-
lia, hemolytic anemia, acute leukemia, cardiac infarction
[43]; the same was observed in a detailed study of mul-
tiple myeloma [115]. A case study demonstrated ability
of thrombodynamics to detect hypercoagulation in beta-
thalassemia [116]; portal vein thrombosis occurred after
several weeks of increased clot growth velocity. In some
of these papers, comparison was done with thrombin
generation and thrombelastography, which did not show
hypercoagulation changes in most cases.
To summarize, thrombodynamics assay shows signifi-
cant promise as a tool to detect hypercoagulation and
evaluate thrombotic risk, but additional clinical research
is needed to establish a reliable relationship between as-
says indicators and thrombosis risks.Flow perfusion chambers
Formation of platelets-and-fibrin thrombi in flow cham-
bers observed by microscopy is potentially an “ultimate”
global assay that is able to evaluate both platelet func-
tions (including adhesion, aggregation, and procoagulant
activity) and blood coagulation. Such microfluidic de-
vices are being actively developed and used for various
applications (see recent review in [116]). Review of this
rapidly developing field is beyond the scope of the
present paper. However, it should be noted that there
are reports on the ability of flow perfusion chambers to
detect hypercoagulation changes in blood [117-119]. How-
ever, there are few clinical studies and standardization sta-
tus of these chambers is very poor [120]. Although
theroretical consideration suggest significant potential of
flow chambers, they have a long way to go in order to be-
come a clinical tool.Conclusions
The first conclusion of the present analysis is that the
claim of the global assays that they can detect functional
hypercoagulation is valid, to a significant degree. Com-
pared with INR and APTT, sensitivity of the new global
assays to hypercoagulation is definitely higher and en-
compasses a wider range of disorders and hypercoagula-
tion causes. It is likely that there are two reasons behind
this. First, these novel assays use smaller concentrations
of activators, which do not obscure the effect of circulat-
ing pro-coagulant material (or, in some cases, activation
and propagation phases are spatially separated). Second,
the parameters provided by new global assays might be
more sensitive than just time of clot formation, andinvolvement of all major reactions makes the assays sen-
sitive to other pro-coagulant changes.
However, there are two major issues that complicate use
of global assays for the evaluation of thrombotic risks.
The most important concern is that conclusion about
sensitivity of the assays is usually reached with large pa-
tient cohorts only, standard deviations are large, and the
differences of mean assay parameters between groups
are significant mostly because of large statistics (Tables 2,
3 and 4). In other words, if we attempt to define bound-
aries and select patient groups with different risks based
on the assay parameters, the overall difference of throm-
botic risk between groups is not usually large. It is ques-
tionable whether this difference is sufficient to affect
clinical decisions. Some of the novel assays show prom-
ise of sensitivity increase, but their clinical utility also re-
mains to be tested directly.
Another concern is lack of standardization. There are
numerous versions for each assay, and clinical investiga-
tions often use different approaches, and the assay sensi-
tivity strongly depends on the protocol used. Therefore,
the results from different papers cited in this review
might be difficult to interpret and to reproduce. The
current attempts at standardization for some of the bet-
ter established global assays such as thrombin generation
[121-123]) make us hope that this might be resolved in
the foreseeable future.
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